164 related articles for article (PubMed ID: 31396634)
1. Circulating Tumour DNA Reflects Tumour Burden Independently of Adverse Events Caused by Systemic Therapies for Melanoma.
Ashida A; Sakaizawa K; Mikoshiba A; Kiniwa Y; Okuyama R
Acta Derm Venereol; 2019 Nov; 99(12):1184-1185. PubMed ID: 31396634
[No Abstract] [Full Text] [Related]
2. Diversity of circulating tumor cells in peripheral blood: Detection of heterogeneous BRAF mutations in a patient with advanced melanoma by single-cell analysis.
Kiniwa Y; Nakamura K; Mikoshiba A; Akiyama Y; Morimoto A; Okuyama R
J Dermatol Sci; 2018 May; 90(2):211-213. PubMed ID: 29426605
[No Abstract] [Full Text] [Related]
3. Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients.
Ashida A; Sakaizawa K; Uhara H; Okuyama R
Acta Derm Venereol; 2017 Nov; 97(10):1212-1218. PubMed ID: 28681063
[TBL] [Abstract][Full Text] [Related]
4. Melanoma with BRAF Mutation in Circulating Cell-free DNA despite no Mutation in the Primary Lesion: A Case Report.
Ashida A; Uhara H; Mikoshiba A; Sakaizawa K; Kumagai N; Koga H; Okuyama R
Acta Derm Venereol; 2016 Jan; 96(1):128-9. PubMed ID: 26123241
[No Abstract] [Full Text] [Related]
5. Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
Seremet T; Planken S; Schreuer M; Jansen Y; Delaunoy M; El Housni H; Lienard D; Del Marmol V; Heimann P; Neyns B
Melanoma Res; 2018 Feb; 28(1):65-70. PubMed ID: 29227333
[TBL] [Abstract][Full Text] [Related]
6. S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma.
Abusaif S; Jradi Z; Held L; Pflugfelder A; Weide B; Meier F; Garbe C; Eigentler TK
Melanoma Res; 2013 Oct; 23(5):396-401. PubMed ID: 23907232
[TBL] [Abstract][Full Text] [Related]
7. Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy.
Haselmann V; Gebhardt C; Brechtel I; Duda A; Czerwinski C; Sucker A; Holland-Letz T; Utikal J; Schadendorf D; Neumaier M
Clin Chem; 2018 May; 64(5):830-842. PubMed ID: 29483107
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors.
Lee JH; Menzies AM; Carlino MS; McEvoy AC; Sandhu S; Weppler AM; Diefenbach RJ; Dawson SJ; Kefford RF; Millward MJ; Al-Ogaili Z; Tra T; Gray ES; Wong SQ; Scolyer RA; Long GV; Rizos H
Clin Cancer Res; 2020 Aug; 26(15):4064-4071. PubMed ID: 32321716
[TBL] [Abstract][Full Text] [Related]
9. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.
Tan L; Sandhu S; Lee RJ; Li J; Callahan J; Ftouni S; Dhomen N; Middlehurst P; Wallace A; Raleigh J; Hatzimihalis A; Henderson MA; Shackleton M; Haydon A; Mar V; Gyorki DE; Oudit D; Dawson MA; Hicks RJ; Lorigan P; McArthur GA; Marais R; Wong SQ; Dawson SJ
Ann Oncol; 2019 May; 30(5):804-814. PubMed ID: 30838379
[TBL] [Abstract][Full Text] [Related]
10. Efficient treatment of a metastatic melanoma patient with a combination of BRAF and MEK inhibitors based on circulating tumor DNA analysis: a case report.
Quéreux G; Herbreteau G; Knol AC; Vallée A; Khammari A; Théoleyre S; Saint-Jean M; Dréno B; Denis MG
BMC Res Notes; 2017 Jul; 10(1):320. PubMed ID: 28743309
[TBL] [Abstract][Full Text] [Related]
11. Quantitative analysis of the BRAF
Ashida A; Sakaizawa K; Mikoshiba A; Uhara H; Okuyama R
Int J Clin Oncol; 2016 Oct; 21(5):981-988. PubMed ID: 27041702
[TBL] [Abstract][Full Text] [Related]
12. Liquid biopsy-based analysis by ddPCR and CAPP-Seq in melanoma patients.
Kaneko A; Kanemaru H; Kajihara I; Mijiddorj T; Miyauchi H; Kuriyama H; Kimura T; Sawamura S; Makino K; Miyashita A; Aoi J; Makino T; Masuguchi S; Fukushima S; Ihn H
J Dermatol Sci; 2021 Jun; 102(3):158-166. PubMed ID: 34049769
[TBL] [Abstract][Full Text] [Related]
13. Vemurafenib-Induced Disseminated Intravascular Coagulation in Metastatic Melanoma.
van den Brom RR; Mäkelburg AB; Schröder CP; de Vries EG; Hospers GA
J Clin Oncol; 2015 Dec; 33(36):e133-4. PubMed ID: 24778390
[No Abstract] [Full Text] [Related]
14. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
15. Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy.
Keller L; Guibert N; Casanova A; Brayer S; Farella M; Delaunay M; Gilhodes J; Martin E; Balagué G; Favre G; Pradines A; Meyer N
Acta Derm Venereol; 2019 Feb; 99(2):206-210. PubMed ID: 30393817
[TBL] [Abstract][Full Text] [Related]
16. Monitoring Melanoma Using Circulating Free DNA.
Diefenbach RJ; Lee JH; Rizos H
Am J Clin Dermatol; 2019 Feb; 20(1):1-12. PubMed ID: 30374893
[TBL] [Abstract][Full Text] [Related]
17. Is it good or bad to find a BRAF mutation?
Flaherty KT
J Clin Oncol; 2011 Apr; 29(10):1229-30. PubMed ID: 21343552
[No Abstract] [Full Text] [Related]
18. Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients.
Marczynski GT; Laus AC; Dos Reis MB; Reis RM; Vazquez VL
Sci Rep; 2020 Oct; 10(1):18682. PubMed ID: 33122747
[TBL] [Abstract][Full Text] [Related]
19. Circulating biomarkers in malignant melanoma.
Alegre E; Sammamed M; Fernández-Landázuri S; Zubiri L; González Á
Adv Clin Chem; 2015; 69():47-89. PubMed ID: 25934359
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the liquid biopsy for the detection of BRAFV600E mutation in metastatic melanoma patients.
Salvianti F; Massi D; De Giorgi V; Gori A; Pazzagli M; Pinzani P
Cancer Biomark; 2019; 26(3):271-279. PubMed ID: 31524142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]